4503 — Astellas Pharma Share News
0.000.00%
Last trade - 00:00Brief: Pfizer And Astellas’ Padcev Plus Keytruda Shows Long-Term Efficacy In First-Line Treatment Of Locally Advanced Or Metastatic Urothelial Cancer
Factbox: All of Donald Trump's tariffs and threatened trade actions
Brief: Astellas Pharma Inc- Recording Of Extraordinary Losses In Non-Consolidated Financial Results
Table: Astellas -9-MTH group results (IFRS)
Factbox: All of Donald Trump's tariff threats
Factbox: All of Donald Trump's tariff threats
Explainer: Trump tariffs on chips and drugs would hit U.S. allies in Asia
Brief: Astellas Pharma Inc- Notice Regarding Progress In Core Business, Impairment Loss And Revision Of Financial Forecasts For Fy2024
Table: Astellas -2024/25 group forecast(IFRS)
Brief: Sangamo Therapeutics & Astellas Enter Capsid License Agreement
Brief: EMA’s PRAC Says Insufficient Evidence to Link Doxycycline To Suicidality Risk
Brief: Astellas Pharma Inc - Update On Izervay (Avacincaptad Pegol Intravitreal Solution) Supplemental New Drug Application
China detains South Korean on suspicion of espionage (updated)
Brief: Astellas Pharma Inc - Update On Marketing Authorization Application For Avacincaptad Pegol (Acp) In The European Union
Brief: Astellas's Vyloy Currently Available At Wholesale Acquisition Cost Of $1600.00 Per 100MG Vial- Spokesperson
FDA approves Astellas' gastric cancer therapy (updated)
FDA approves Astellas' gastric cancer therapy
Brief: FDA Approves Astellas' Vyloy For A Type Of Gastroesophageal Junction Adenocarcinoma
Brief: Japan's Astellas To Close Biopharmaceutical Manufacturing Facility In California This Fiscal Year, Nikkei Says